替加色罗心血管安全性再评估:临床试验数据回顾
本文回顾了2018年FDA胃肠药物咨询委员会会议的两项外部裁定数据,评估替加色罗的心血管安全性。共纳入18,645例患者(替加色罗11,614例,安慰剂7,031例)。两次独立外部裁定显示,在无心血管缺血事件史且心血管危险因素≤1个的<65岁女性便秘型肠易激综合征患者中,替加色罗未发生主要不良心血管事件,支持其在该人群中的安全性。
要点
- 替加色罗适用于<65岁、无心血管缺血事件史、危险因素≤1个的便秘型IBS女性。
- 两次外部裁定中,替加色罗组冠状动脉或脑血管缺血事件发生率0.06%,安慰剂组0.01%,差异无统计学意义。
- 所有报告心血管事件的替加色罗患者均至少有1个心血管危险因素。
核心结论
- 两项独立外部裁定表明,在<65岁、无心血管缺血事件史且心血管危险因素≤1个的便秘型肠易激综合征女性中,替加色罗是安全的。
研究设计与样本
- 研究基于2018年胃肠药物咨询委员会会议的两项外部裁定数据,纳入18,645例患者(替加色罗11,614例,安慰剂7,031例)。
- 第一次外部裁定评估内部识别的24例可能心血管缺血事件(替加色罗20例,安慰剂4例),第二次独立外部裁定进一步评估这些事件。
主要发现
- 第一次裁定识别14例(0.075%)事件:替加色罗13例(0.11%),安慰剂1例(0.014%);所有患者均有≥1个心血管危险因素,其中11例有≥2个。
- 第二次裁定识别390例事件,其中24例(0.13%)被分类为可能的新发或恶化事件:替加色罗18例(0.16%),安慰剂6例(0.09%)。
- 所有报告心血管事件的替加色罗患者均至少有1个危险因素,包括心血管疾病、高脂血症、年龄≥55岁、高血压、糖尿病、肥胖和吸烟。
关键数值与推荐
- 在<65岁、无心血管缺血事件史且心血管危险因素≤1个的便秘型肠易激综合征女性中,接受替加色罗治疗未发生主要不良心血管事件。
临床怎么用
- 临床使用替加色罗时,应严格筛选适用人群:<65岁女性、无心血管缺血事件史、心血管危险因素≤1个。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Tegaserod is a 5-HT4 receptor agonist approved for irritable bowel syndrome with constipation in women <65 years of age without a history of cardiovascular ischemic events. Safety data are presented from 2 external adjudications from the 2018 Gastrointestinal Drugs Advisory Committee meeting supporting tegaserod's reintroduction after its voluntary 2007 withdrawal. Withdrawal was based on an internal adjudication using pooled placebo-controlled tegaserod data to identify potential cardiovascular ischemic signals. METHODS: An independent committee conducted an external adjudication to evaluate 24 possible cardiovascular ischemic events (tegaserod: n = 20; placebo: n = 4) identified internally. A second independent external adjudication further evaluated these events. RESULTS: A total of 18,645 patients were included (tegaserod: n = 11,614; placebo: n = 7031). The first adjudication identified 14 (0.075%) events (tegaserod: n = 13 [0.11%]; placebo: n = 1 [0.014%]). All patients had ≥1 cardiovascular risk factor, and 11 had ≥2. The second adjudication identified 390 events, 24 (0.13%) were classified as probable new or worsening events (tegaserod: 18 [0.16%]; placebo: 6 [0.09%]). For tegaserod, 7 (0.06%) were coronary or cerebrovascular ischemic events compared with 1 (0.01%) for placebo (odds ratio, 4.24; 95% confidence interval, 0.52-34.74; P = .273). All tegaserod patients reporting cardiovascular events had ≥1 risk, including cardiovascular disease, hyperlipidemia, ≥55 years of age, hypertension, diabetes, obesity, and smoking. Women <65 years of age without a history of cardiovascular ischemic events and ≤1 cardiovascular risk factor receiving tegaserod experienced no major adverse cardiovascular event(s). CONCLUSIONS: Two independent, external adjudications suggest that tegaserod is safe for women <65 years of age with irritable bowel syndrome with constipation, no history of cardiovascular ischemic events, and ≤1 cardiovascular risk factor.
引用
- Lacy BE, Brenner DM, Chey WD, et al. Re-evaluation of the Cardiovascular Safety Profile of Tegaserod: A Review of the Clinical Data. Clin Gastroenterol Hepatol. 2021. PMID: 34048937. doi:10.1016/j.cgh.2021.05.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。